GLP-1 and Cancer Risk: The Epidemiological Evidence (Positive and Concerning)

The relationship between GLP-1 drugs and cancer may be the most consequential unanswered question in the field. Emerging evidence from large observational studies and a fresh ASCO 2026 analysis suggests GLP-1s may reduce the risk of multiple cancer types. But a meta-analysis of RCTs found a statistically significant increase in thyroid cancer. Both signals demand careful scrutiny.^1,4

The Positive Signal: Reduced Cancer Incidence

A JAMA Oncology study (August 2025) followed 86,632 propensity-score-matched patients — 43,317 on GLP-1 agonists vs. 43,315 non-users. The cumulative cancer incidence was 13.6 per 1,000 person-years among GLP-1 users versus 16.4 for non-users (HR 0.83, P=0.002) — a 17% overall reduction.¹

An ASCO 2026 analysis of seven cancer types found that patients taking GLP-1s were 38–50% less likely to develop stage IV disease in lung, breast, colorectal, and liver cancers. High tumor GLP-1 receptor expression was associated with 33% lower mortality overall and 45% lower mortality in breast cancer.²

At the ASCO GI Cancers Symposium (January 2026), GLP-1 users were found to be 36% less likely to develop colorectal cancer compared to aspirin users — a striking finding given that aspirin has been used for colorectal cancer prevention in certain populations.³

A comprehensive meta-analysis found GLP-1 use was not associated with increased overall GI cancer risk (HR 0.81), with specific reductions in colorectal cancer (HR 0.81) and liver cancer (HR 0.74).⁵

The Concerning Signal: Thyroid Cancer

A meta-analysis of randomized controlled trials published in Diabetes, Obesity and Metabolism (2025) found a statistically significant increase in thyroid cancer incidence among GLP-1 RA users: OR 1.55 (95% CI 1.05–2.27, P=0.03). The effect was more pronounced in longer-duration trials.⁴

This finding aligns with the mechanism-based concern that prompted the FDA to include a boxed warning on all GLP-1 medications about thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). In rodent studies, semaglutide and other GLP-1 agonists caused dose-dependent thyroid C-cell tumors. Whether this translates to humans remains uncertain, but the RCT meta-analysis signal is the first human data suggesting it might.⁶

Mechanism: Why Would GLP-1s Affect Cancer?

Three hypotheses are being investigated:

1. Weight loss effect: Obesity is a known risk factor for 13 cancer types. GLP-1-driven weight loss reduces chronic inflammation, insulin resistance, and circulating insulin — all of which promote cancer growth. This is the simplest explanation.

2. Direct anti-inflammatory effect: GLP-1 agonists reduce CRP and TNF-alpha independent of weight loss (as shown in the anti-inflammatory meta-analysis). Chronic inflammation drives cancer progression.

3. Direct GLP-1 receptor signaling: GLP-1 receptors are expressed on tumor cells. Animal models suggest GLP-1 agonists may have direct anti-proliferative effects independent of obesity or inflammation. The ASCO 2026 finding that high tumor GLP-1R expression correlates with lower mortality supports this hypothesis.²

The honest answer is that we don't yet know which mechanism — or combination — is responsible. The evidence is strong enough to warrant dedicated cancer-endpoint trials but not strong enough to recommend GLP-1s as cancer prevention drugs.